Calico News and Activities

Calico is owned by Alphabet Inc.

Alphabet Inc is one of the...

• Forbes Global 2000 (#9);
• Fortune 500 (#7);
• Global Fortune 500 (#13);
• Nasdaq 100;
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Alphabet Inc is a company listed under the stock ticker GOOGL (US).

Alphabet Inc has a direct presence in 27 countries.

Alphabet Inc has 84 subsidiaries including Calico, CapitalG and Dandelion Energy.

They are in:

• Communication & Sales44%
• Software31%
• Other26%

Acquisition, funding and merger involving Alphabet Inc.

• Alphabet Inc has acquired Wiz (posted on March 13 2026).
• Alphabet Inc has announced the acquisition of Intersect Power  (posted on December 23 2025).
• Alphabet Inc has announced the acquisition of Wiz  (posted on March 20 2025).

View the org chart displaying its 14 main executives

Most searched biographies at Calico

• Arthur Levinson, Chief Executive Officer
• John Whiting, Chief Financial Officer
• Jonathan Lewis, Chief Business Officer

Popular executive movements at Calico

• Joseph Arron has joined the company as Head of Human Biology and Genetics  (posted on February 6 2026).
• Philip Kym has joined the company as Head, Drug Discovery  (posted on October 17 2025).

Create your alert
to follow the executive moves at Calico.

Alphabet Inc has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Calico

• Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease has been Selected for the FDA START Pilot Program - Calico
• Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease - Calico
• Calico Appoints Joseph R. Arron, M.D., Ph.D., as Head of Human Biology and Genetics - Calico
• Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease - Calico
• Calico Appoints Joseph R. Arron, M.D., Ph.D., as Head of Human Biology and Genetics - Calico
• Calico Appoints Philip R. Kym, Ph.D., as Head of Drug Discovery - Calico
• Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease - Calico
• Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease has been Selected for the FDA START Pilot Program - Calico
• Calico and Broad Institute Extend Collaboration Adding Focus on Age-Related Neurodegeneration - Calico
• The HEALEY ALS Platform Trial completes enrollment for testing investigational product ABBV-CLS-7262 from Calico Life Sciences  - Calico
• View more press releases Close

Social media about Calico

• Calico on Wikipedia, Google News & Yahoo Finance
• Calico on LinkedIn, X (Twitter) & YouTube